Interim Report January-March 2024

GOTHENBURG, SWEDEN / ACCESSWIRE / April 24, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)First quarter 2024 (Jan 1 - Mar 31)• Net sales amounted to SEK 186.0 million (140.6), corresponding to an increase of 32 percent in SEK and …
Jetzt den vollständigen Artikel lesen